^
    2d
    Chidamide combined with fulvestrant in the treatment of HR-positive, HER2-negative advanced breast cancer after failure of previous endocrine therapy: a single-arm, single-center, phase 2 study. (PubMed, Breast Cancer Res)
    Chidamide combined with fulvestrant showed encouraging antitumor activity and tolerable toxicity in pts with HR + /HER2- advanced breast cancer that had progressed after previous endocrine therapy. Trial registration ChiCTR2100044282, registered on March 14th 2021.
    P2 data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    fulvestrant • Epidaza (chidamide)
    4d
    Combined oral PI3Kδ inhibitor linperlisib and HDAC inhibitor chidamide in relapsed/refractory peripheral T-cell lymphoma: a multicenter phase 1 trial. (PubMed, Leuk Lymphoma)
    With a median follow-up time of 13.0 months, median duration of response (DOR), progression-free survival, and overall survival (OS) were not reached. In conclusion, linperlisib plus chidamide demonstrated a favorable safety profile and encouraging preliminary efficacy in r/r PTCL.
    P1 data • Journal
    |
    PIK3CD (Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Delta)
    |
    Epidaza (chidamide) • Itari (linperlisib)
    5d
    Born with two faces: sequential DLBCL, NOS and TFHL-AI with TET2 mutation - a case report. (PubMed, Front Immunol)
    He achieved complete remission following six cycles of R-CHOP chemotherapy (rituximab, cyclophosphamide, vindesine, liposomal doxorubicin, and dexamethasone)...He received four cycles of the histone deacetylase inhibitor (HDACi) chidamide combined with COEP chemotherapy (cyclophosphamide, vindesine, etoposide, and prednisone), resulting in a partial remission...Although the prognosis is generally poor, treatment combining HDAC inhibitors such as chidamide with chemotherapy may offer therapeutic potential. Further studies are needed to clarify the molecular mechanisms underlying such lymphoid evolution and to guide optimal management.
    Journal
    |
    TET2 (Tet Methylcytosine Dioxygenase 2)
    |
    TET2 mutation
    |
    Rituxan (rituximab) • cyclophosphamide • etoposide IV • prednisone • Epidaza (chidamide) • vindesine
    15d
    HDAC3 inhibition as a therapeutic strategy in T-cell acute lymphoblastic leukemia via the TYK2-STAT1-BCL2 signaling pathway. (PubMed, Front Immunol)
    HDAC3 was found to associate with TYK2 and contributed to activation of the TYK2-STAT1-BCL2 signaling pathway in T-ALL cells. Our results highlight the effectiveness of the combination of chidamide and chemotherapy in the treatment of T-ALL patients and suggest that HDAC3 can act as a potential novel therapeutic target to inhibit the TYK2-STAT1-BCL2 signaling pathway in T-ALL.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • HDAC2 (Histone deacetylase 2) • TYK2 (Tyrosine Kinase 2) • HDAC10 (Histone Deacetylase 10) • HDAC3 (Histone Deacetylase 3)
    |
    Epidaza (chidamide)
    17d
    Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients With Double-Expressor DLBCL (clinicaltrials.gov)
    P1/2, N=68, Not yet recruiting, Sun Yat-sen University
    New P1/2 trial • IO biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2)
    |
    Rituxan (rituximab) • Epidaza (chidamide) • Polivy (polatuzumab vedotin-piiq)
    17d
    A Prospective, Single-Arm, Multicenter, Phase II Clinical Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer With Acquired Resistance to Immunotherapy and High YAP Protein Expression (clinicaltrials.gov)
    P2, N=32, Not yet recruiting, Guangdong Association of Clinical Trials
    New P2 trial • IO biomarker
    |
    Epidaza (chidamide) • Yidafan (ivonescimab)
    23d
    BiTE (CD3×EGFR)-Based Triplet Therapy Unlocks CD40/CD40L Crosstalk to Revert Immunosuppression in third-generation EGFR-TKI-Refractory NSCLC. (PubMed, J Thorac Oncol)
    This study establishes a novel triple therapy that overcomes the limitations of BiTEs in cold and immunosuppressive TMEs and provides an immunomodulatory approach to addressing third-generation EGFR-TKI resistance.
    Journal
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD40LG (CD40 ligand)
    |
    Tagrisso (osimertinib) • Epidaza (chidamide) • BC3448 • simmitinib (SYHA1817)
    25d
    CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL (clinicaltrials.gov)
    P2, N=58, Recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • Epidaza (chidamide) • Polivy (polatuzumab vedotin-piiq)
    1m
    Chidamide and Anlotinib act synergistically in Jurkat cells by inhibiting the Hippo signaling pathway. (PubMed, Biochem Biophys Rep)
    To overcome these limitations, we systematically evaluated the synergistic Combination effects of three drug candidates, OTX-015 (BET inhibitor), Metformin (metabolic regulator), and Anlotinib (multitargeted tyrosine kinase inhibitor), with Chidamide. Chidamide and Anlotinib synergistically inhibit Hippo signaling pathway, which reveals a novel "dual epigenetic kinase targeting" strategy for the treatment of T-ALL. Future studies should validate these findings in vivo and investigate the impact of the metabolic microenvironment on therapeutic efficacy.
    Journal
    |
    CTGF (Connective tissue growth factor)
    |
    Focus V (anlotinib) • Epidaza (chidamide) • birabresib (OTX015) • metformin
    1m
    PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL (clinicaltrials.gov)
    P2, N=47, Not yet recruiting, Ruijin Hospital
    New P2 trial
    |
    Epidaza (chidamide) • golidocitinib (DZD4205)
    1m
    A Prospective, Single-Arm, Multicenter Clinical Study of Chidamide, Decitabine, PD-1 Monoclonal Antibody Combined with Pegaspargase (Epi-Immuno-Pe) in Elderly/Chemotherapy-Intolerant Patients with Relapsed or Refractory NK/T-Cell Lymphoma (ChiCTR2600117389)
    P=N/A, N=20, Not yet recruiting, The First Affiliated Hospital, Zhejiang University School of Medicine; The First Affiliated Hospital, Zhejiang University School of Medicine
    New trial
    |
    decitabine • Epidaza (chidamide) • Oncaspar liquid (pegaspargase)